Welcome to the ATTD 2022 Interactive Program
The conference will officially run on Central European Summer Time (UTC+2) - Barcelona Time
To convert the conference times to your local time Click Here
It is estimated that more than 160 million patients worldwide live with chronic kidney disease and type 2 diabetes. They are at high risk for cardiovascular events and progressive renal failure. Unmet educational needs of HCPs include optimizing management of chronic kidney disease and Type 2 diabetes will be summarized. With the development of nonsteroidal mineralocorticoid receptor antagonists (MRA), the safety profile of MRA has also improved significantly, making mineralocorticoid receptor antagonism a potential, highly effective treatment option for slowing the progression of CKD in T2D. Finerenone is such novel nonsteroidal selective MRA with a high MR selectivity compared to spironolactone. It has favourable effects on cardiorenal outcomes in patients with stage 3 or 4 chronic kidney disease with increased albuminuria and type 2 diabetes. Two large trials ((FIDELIO-DKD, FIGARO-DKD) evaluated the effects of Finerenone on cardiorenal outcomes and demonstrated significant favourable effects. Results of these studies will be discussed. New treatment approaches for chronic kidney disease in diabetes will be highlighted.